KNIGHT CAPITOL CONSULTANTS for REGENXBIO
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDAcAAP-approved products under certain circumstances.) Potential amendments to the Food, Drug and Cosmetic Act, the Public Health Service Act, or the Social Security Act that would impact the provision of cell and gene therapies (no specific legislation):. -
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director - Senator Orrin Hatch |
Medicare/Medicaid MMM
Potential amendments to the Social Security Act to allow value-based pricing under Medicaid (HR 2666)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Pharmacy PHA
Development of legislation that would affect the research, regulation or pricing of biopharmaceuticals, including implementation of the Inflation Reduction Act (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin G. Hatch; Health Policy Director, Senator Orrin G. Hatch |
Taxation/Internal Revenue Code TAX
Monitor discussion of proposals to affect the R&D Tax Credit (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Chief of Staff, Senator Orrin Hatch; Health Policy Director, Senator Orrin Hatch. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.